LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

9 May 2017

New LiDCOunity v2 monitor launch

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has been granted a CE mark for its latest product, the LiDCOunity v2 and will showcase it in Europe at the 5th ERAS World Congress, which will be held in Lyon, France from 10-12 May 2017.

Enhanced Recovery After Surgery ("ERAS") is a well-established multimodal, evidence-based, perioperative care pathway designed to improve recovery after surgery. LiDCO technology has been used in published clinical research as a key component of ERAS care pathways. The ERAS World Congress is organised by The ERAS Society, a not for profit academic society working to implement best practice in surgical care worldwide.

Built on a striking new slim widescreen monitor platform the LiDCOunity v2 incorporates the core value proposition of combining the full suite of LiDCO technology into one offering. Bringing together LiDCO's non-invasive, minimally invasive and calibrated technologies it allows continuous hemodynamic monitoring, including monitoring of level of consciousness across the entire clinical pathway in one monitor. In addition it has a number of new additional features, such as an updated graphical user interface with a more intuitive menu system, internal battery for transportation and new clinical guidance protocols to aid users.

More information about LiDCOunity V2 can be found on our new website www.lidco.com

Commenting on the new product, Matt Sassone, Chief Executive Officer of LiDCO, said: "The 5th ERAS World Congress is the perfect platform to showcase our new LiDCOunity v2 monitor to our key target audience. Initial feedback to the new look and features has been extremely positive. The commercial launch is another important step in maintaining our technology leadership position in the growing hemodynamic monitoring market."

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.